http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-0882727-B9
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f7c7159366be37ecf8a4c595cfa235a8 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D473-30 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D473-34 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D473-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-04 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D473-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D473-34 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D473-30 |
| filingDate | 1997-07-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2005-06-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_72a0745c7f0f7a7d592ffaa17763dc72 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c4c1c78fb29d817d865adda7a45650f9 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_559e2e7bf53461fffadae0ba141180d7 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_785ad4bde17166fea42a4a5ef1085283 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b7a7c84d09c59cb28b4ffbe610473b1a http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_353c9d2047b280d9edb3ab17f795adac http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e5cf507c1cc5d5781984d1479db41197 |
| publicationDate | 2005-06-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | EP-0882727-B9 |
| titleOfInvention | Novel purine derivatives |
| abstract | A purine derivative represented by the following general formula (I): <CHEM> wherein R<2> is a hydrogen atom or a hydrocarbon group containing at most 14 carbon atoms; any -CH2- group in said hydrocarbon group may be replaced with a carbonyl group, a sulfonyl group, -O- or -S- when said -CH2- group is not directly attached to the purine ring or is in -CH3 group not directly attached to the purine ring; any =CH2 group may be replaced with =O or =S; C-H group in said hydrocarbon group may be replaced with N, a C-halogen group or a C-CN group when said C-H group is in -CH2-group not directly attached to the purine ring, in -CH3 group not directly attached to the purine ring, in >CH-group not directly attached to the purine ring, in =CH-group not directly attached to the purine ring or in =CH2 group; R<6> is a hydroxyl group, an amino group or an amino group mono- or di-substituted with a hydrocarbon group containing at most 10 carbon atoms; R<8> is a hydroxyl group, a mercapto group, an acyloxy group containing at most 18 carbon atoms or an oxycarbonyloxy group substituted with a hydrocarbon group containing at most 19 carbon atoms; R<9> is a hydrocarbon group containing at most 14 carbon atoms; any -CH2- group in said R<9> may be replaced with a carbonyl group, a sulfonyl group, -O- or -S- when said -CH2- group is not directly attached to the purine ring or is in -CH3 group not directly attached to the purine ring; any =CH2 group may be replaced with =O or =S; C-H group in said R<9> may be replaced with N, a C-halogen group or a C-CN group when said C-H group is in -CH2-group not directly attached to the purine ring, in -CH3 group not directly attached to the purine ring, in >CH-group not directly attached to the purine ring, in =CH-group not directly attached to the purine ring, in =CH2 group or in IDENTICAL CH group; or its tautomer or pharmaceutically acceptable salts thereof, and an interferon inducer, an anti-virus agent or an anti-cancer agent which comprises said purine derivative or pharmaceutically acceptable salts thereof as an active ingredient. |
| priorityDate | 1996-07-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 1016.